STIMULUS includes academic scientists with a proven track record in the synthesis, application, and testing of novel materials for bacterial detection and control from across Europe. Six countries are represented: Austria, Germany, the Netherlands, Switzerland, Turkey, and the United Kingdom.

​

All our early-stage researchers will receive a Ph.D. degree from one of our leading academic institutions: Academic Medical Center (Amsterdam), Koç University, Technical University of Darmstadt, University of Bath,  University of Natural Resources and Life Sciences Vienna , or University of Siegen.

​

To ensure the relevance of our research and take it to translation, our consortium includes many clinical and industrial partners. These partners contribute to both the research and training of our early-stage researchers.

​

Clinical partners Royal Bristol Children’s Hospital (BCH) and Diakonie Klinikum Siegen (DKS) will inform the consortium and ensure that the research output has clinical utility. The Academic Medical Centre (AMC) is a research centre and hospital with expertise in infection models (in-vitro and in-vivo), the clinical applications of research, and a leading developer of novel highly potent antimicrobials.

​

Our industry partners include research-intensive SMEs (Polymun GmbH, Atto-Tec GmbH), multi-national wound dressing companies (Hartmann AG), and advanced materials companies (SEFAR AG, Nanostone Water GmbH, Glatfelter Inc.).

​

STIMULUS also includes the Department of Health and Social Care in the UK, which brings the expertise of working on antibiotic public policy and experience of fundamental research in biofilms and infection.

​

We aim to maximize the innovative potential of the consortium and its early-stage researchers. Therefore, STIMULUS also includes training on IP and entrepreneurship by technology transfer experts from LES Turkey and the KWORKS accelerator.

​

STIMULUS goals are ambitious, and the broad competence of our partners is crucial.